Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease

PURPOSE: Progressive malignancy is the leading cause of death after allogeneic hematopoietic stem-cell transplantation (alloHSCT). After alloHSCT, B-cell malignancies often are treated with unmanipulated donor lymphocyte infusions (DLIs) from the transplant donor. DLIs frequently are not effective a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Autores principales: Brudno, Jennifer N., Somerville, Robert P.T., Shi, Victoria, Rose, Jeremy J., Halverson, David C., Fowler, Daniel H., Gea-Banacloche, Juan C., Pavletic, Steven Z., Hickstein, Dennis D., Lu, Tangying L., Feldman, Steven A., Iwamoto, Alexander T., Kurlander, Roger, Maric, Irina, Goy, Andre, Hansen, Brenna G., Wilder, Jennifer S., Blacklock-Schuver, Bazetta, Hakim, Frances T., Rosenberg, Steven A., Gress, Ronald E., Kochenderfer, James N.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2016
Materias:
ORIGINAL REPORTS
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4872017/
https://ncbi.nlm.nih.gov/pubmed/26811520
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.64.5929
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares